Skip to main content

Advertisement

Table 1 Demographics and clinical characteristics of study subjects (n = 202)

From: Sleep experiences during different lifetime periods and in vivo Alzheimer pathologies

Age, years 71.07 (6.74)
Female 102 (50.5%)
Education level, years 11.51 (4.77)
APOE4 carrier 37 (18.3%)
Vascular risk score, % 17.49 (15.84)
HDRS 0.74 (1.51)
Current use of any sleep medication 6 (3.0%)
Bad sleep quality (bad + very bad)
 Young adulthood 13 (6.4%)
 Midlife 21 (10.4%)
 Current 24 (11.9%)
Sleep duration, h
 Young adulthood 6.83 (1.11)
 Midlife 6.65 (1.18)
 Current 6.42 (1.31)
Aβ positive 33 (16.3%)
Global Aβ deposition 1.20 (0.25)
AD-ND positive 112 (55.4%)
AD-CM 1.41 (0.12)
AD-CT, mm 2.84 (0.18)
  1. Data are presented as mean (standard deviation) or number (%)
  2. APOE4 apolipoprotein E ε4, HDRS Hamilton Depression Rating Score, beta-amyloid, AD-ND Alzheimer’s disease signature region neurodegeneration, AD-CM Alzheimer disease signature region cerebral glucose metabolism, AD-CT Alzheimer’s disease signature region cortical thickness